Molecular Biology and Cell Biology expertise: Experienced with primary cell culture, transient and stable transfection, genome editing technology (CRISPR/Cas9), very experienced with all common molecular biology methods, very experienced with biochemical and immunological techniques, very experienced with immunofluorescent staining and imaging, very experienced with flow cytometry/FACS. Biomarker Profiling and Innovative Drug Design: Screened and identified nanoparticle (exosome) carried biomessengers for fibrotic disease diagnosis, prognosis and treatment guidance. Animal Model Experience: Successfully achieved genetic modification of transgenic and knock out animal models such as fibrosis, lipid / cholesterol metabolism disorders, etc., as well as in vivo nanovesicular delivery of anti-fibrogenetic agents to different organs to treat fibrosis and in vitro test of nanovesical delivery of drugs. Built liver fibrotic animal models, such as CCl4- and TAA-induced mice models. Also created alcoholic liver disease models, including chronic ethanol administration by intragastric delivery, and gained expertise with hepatectomy surgery for liver regeneration animal models.Primary cell isolation experience: Stem cell Organoid culture. Possess extensive experience in the development of primary cell models, including cell culture in 2-D and 3-D for cytotoxicity and optimization of drug delivery device using molecular biology techniques such as gene cloning, vector construction, in-situ hybridization, microRNA assay, etc. Project Leadership & Coordination: Prepared research papers including study concept and design, acquisition of data, analysis and interpretation of data, manuscript draft. Drafted grant. Coordinated communication between research team and clinical staff, and worked closely with physicians to set up inclusion and exclusion criteria in this serum biomarker discovery study.